Barinthus Biotherapeutics (NASDAQ:BRNS) Stock Rating Upgraded by Zacks Research

Barinthus Biotherapeutics (NASDAQ:BRNS) was upgraded by equities research analysts at Zacks Research to a “hold” rating in a research report issued to clients and investors on Wednesday,Zacks.com reports.

Separately, Weiss Ratings upgraded Barinthus Biotherapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $4.00.

Barinthus Biotherapeutics Price Performance

NASDAQ BRNS opened at $0.73 on Wednesday. The stock has a market capitalization of $29.87 million, a P/E ratio of -0.71 and a beta of -0.39. The firm’s 50-day moving average is $0.62 and its two-hundred day moving average is $0.63. Barinthus Biotherapeutics has a 12 month low of $0.51 and a 12 month high of $1.83.

Barinthus Biotherapeutics (NASDAQ:BRNS) last announced its quarterly earnings results on Friday, August 7th. The company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.02. As a group, analysts anticipate that Barinthus Biotherapeutics will post -0.93 EPS for the current year.

Hedge Funds Weigh In On Barinthus Biotherapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in BRNS. Baird Financial Group Inc. grew its stake in shares of Barinthus Biotherapeutics by 108.2% in the second quarter. Baird Financial Group Inc. now owns 192,461 shares of the company’s stock worth $179,000 after acquiring an additional 100,000 shares in the last quarter. Renaissance Technologies LLC raised its stake in shares of Barinthus Biotherapeutics by 115.8% in the fourth quarter. Renaissance Technologies LLC now owns 143,100 shares of the company’s stock valued at $100,000 after acquiring an additional 76,800 shares in the last quarter. Finally, Rangeley Capital LLC boosted its holdings in Barinthus Biotherapeutics by 88.8% in the first quarter. Rangeley Capital LLC now owns 159,465 shares of the company’s stock valued at $91,000 after purchasing an additional 75,024 shares during the period. Hedge funds and other institutional investors own 25.20% of the company’s stock.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.